Seletracetam is a pyrrolidone derivative and with a structural similarity to newer generation antiepileptic drug levetiracetam. It binds to the same target as levetiracetam but with higher affinity and has... It binds to the same target as levetiracetam but with higher affinity and has shown potent seizure suppression in models of acquired and genetic epilepsy with high CNS tolerability.
- Mechanism
- Curator reviewed
Seletracetam binds to SV2A in a stereospecific and selective manner. SV2A is a membrane glycoprotein present in synaptic vesicles of neurons that plays a role as calcium regulators in neurotransmitter release and modulate synaptic networks. Seletracetam is thought to reduce excessive neuronal activity by modulating SV2A function and restoring the ability of a neuron to regulate its neurotransmitter release. Seizure generation induces a sustained membrane depolarization causing a prolonged firing of voltage-dependent calcium currents sufficient to induce a significant rise in calcium concentration. High voltage-activated calcium currents are inhibited by seletracetam by blocking N-type calcium channels in the pyramidal neurons. The drug reduces the degree of calcium influx and decreases the intraneuronal calcium concentration, blocking the abnormal fluctuations in membrane potential occurring during epileptic discharges.
- Primary indication
- Investigated for use/treatment in epilepsy.Curator reviewed
- Formula / weight
- C10H14F2N2O2 · 232.2272 g/mol (avg)
- Code names
- UCB-44212
Resolves to
ANWPENAPCIFDSZ-RQJHMYQMSA-NSMILESCC[C@H](N1C[C@@H](CC1=O)C=C(F)F)C(N)=OWhat you can answer from here — as of February 03, 2022
Which drugs share a target with Seletracetam, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account